Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4,499 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.7
Industry P/E
--
EV/EBITDA
-6.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.7
Face value
--
Shares outstanding
82,324,445
CFO
$-433.00 Mln
EBITDA
$-592.48 Mln
Net Profit
$-570.63 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akero Therapeutics (AKRO)
| 96.4 | 1.1 | 22.6 | 75.7 | 7.8 | 14.0 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Akero Therapeutics (AKRO)
| 19.0 | -57.4 | 159.1 | -18.0 | 16.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akero Therapeutics (AKRO)
|
54.7 | 4,499.0 | 0.0 | -292.8 | -7,205,162.5 | -28.7 | -- | 4.7 |
| 4.4 | 96.3 | -3.6 | -204.4 | 4,048.0 | -- | -- | 0.9 | |
| 1.6 | 116.1 | 0.4 | -98.2 | -10,576.5 | -834.6 | -- | 27.3 |
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that... protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S. Read more
President, CEO & Director
Dr. Andrew Cheng M.D., Ph.D.
President, CEO & Director
Dr. Andrew Cheng M.D., Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Akero Therapeutics Inc (AKRO) is $54.65 (NASDAQ) as of 09-Dec-2025 09:30 EDT. Akero Therapeutics Inc (AKRO) has given a return of 7.82% in the last 3 years.
Since, TTM earnings of Akero Therapeutics Inc (AKRO) is negative, P/E ratio is not available.
The P/B ratio of Akero Therapeutics Inc (AKRO) is 4.70 times as on 09-Dec-2025, a 19 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-7.79
|
2.62
|
|
2023
|
-8.57
|
2.43
|
|
2022
|
-22.87
|
7.85
|
|
2021
|
-7.32
|
4.36
|
|
2020
|
-11.30
|
3.46
|
The 52-week high and low of Akero Therapeutics Inc (AKRO) are Rs 58.40 and Rs 21.34 as of 03-Apr-2026.
Akero Therapeutics Inc (AKRO) has a market capitalisation of $ 4,499 Mln as on 09-Dec-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Akero Therapeutics Inc (AKRO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.